open access

Vol 60, No 3 (2001)
ORIGINAL ARTICLES
Published online: 2001-05-29
Submitted: 2012-02-06
Get Citation

Effect of cladribine treatment on ß-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis

Adam Niezgoda, Jacek Losy, Pankaj D Mehta
Folia Morphol 2001;60(3):225-228.

open access

Vol 60, No 3 (2001)
ORIGINAL ARTICLES
Published online: 2001-05-29
Submitted: 2012-02-06

Abstract

β-2 Microglobulin ( β2M) is a low molecular weight protein located extracellularly and associated with class 1 antigens of the major histocompatibility complex and is considered a marker for disease activity in immune disorders. Cladribine (2-chloro-2-deoxyadenosine, 2-CDA) is a potent lymphocytotoxic agent under investigation in the treatment in MS patients. As β2M levels may indicate inflammatory events in CNS we determined CSF- β2M and serum β2M levels in patients with relapsing-remitting MS before and after cladribine treatment as well as in a control group. There was a significant β2M decrease in sera but not in CSF in MS patients after the cladribine treatment, associated with a slight but significant clinical improvement measured by Kurtzke's Expanded Disability Status Scale. We also found a significant decrease in sICAM-1 level in CSF but not in sera in MS patients. The data support a role of cladribine in MS therapy and deliver new information on cladribine immunological effects in MS patients.

Abstract

β-2 Microglobulin ( β2M) is a low molecular weight protein located extracellularly and associated with class 1 antigens of the major histocompatibility complex and is considered a marker for disease activity in immune disorders. Cladribine (2-chloro-2-deoxyadenosine, 2-CDA) is a potent lymphocytotoxic agent under investigation in the treatment in MS patients. As β2M levels may indicate inflammatory events in CNS we determined CSF- β2M and serum β2M levels in patients with relapsing-remitting MS before and after cladribine treatment as well as in a control group. There was a significant β2M decrease in sera but not in CSF in MS patients after the cladribine treatment, associated with a slight but significant clinical improvement measured by Kurtzke's Expanded Disability Status Scale. We also found a significant decrease in sICAM-1 level in CSF but not in sera in MS patients. The data support a role of cladribine in MS therapy and deliver new information on cladribine immunological effects in MS patients.
Get Citation

Keywords

multiple sclerosis; ß-2 microglobuline; cladribine; ICAM-1

About this article
Title

Effect of cladribine treatment on ß-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis

Journal

Folia Morphologica

Issue

Vol 60, No 3 (2001)

Pages

225-228

Published online

2001-05-29

Bibliographic record

Folia Morphol 2001;60(3):225-228.

Keywords

multiple sclerosis
ß-2 microglobuline
cladribine
ICAM-1

Authors

Adam Niezgoda
Jacek Losy
Pankaj D Mehta

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By  "Via Medica sp. z o.o." sp.k., Świętokrzyska 73, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl